Cargando…
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation carrier-added Lu-177. PRRT has recently been developed...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659917/ https://www.ncbi.nlm.nih.gov/pubmed/36387893 http://dx.doi.org/10.3389/fendo.2022.941832 |